^
Association details:
| Biomarker: | SRC overexpression + BRAF V600E |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Molecular characterization of BRAF(V600E) CRC in response to Src-targeted therapy in vitro
Published date:
05/28/2021
Excerpt:
BRAFV600E and wild type (WT) CRC cell lines were treated with Dasatinib...Src overexpression is responsible of the acquired resistance to Dasatinib and regulates several pathways that could be involved in the tumorigenesis of BRAF mutated CRC.
